You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Avid Bioservices, Inc. Returns vs. S&P
|1 Year||5 Year||5 Year Annualized||Since IPO|
Avid Bioservices, Inc. Company Info
News & Analysis
The stock will be part of a well-known index.
The company reported great fiscal 2021 Q2 results.
The company still had significant production problems. But it also picked up a lot of new business in Q4.
These two businesses offer compelling growth potential, but one has yet to deliver on its promise and the other just became more complicated thanks to the coronavirus pandemic.
The drug manufacturer encountered an operational setback, which forced it to slash revenue guidance.
These two small-cap stocks are risky, but not as risky as penny stocks. And buying a small stake in either company could actually pay off for patient investors.
The drug manufacturing company reported operating results for its fiscal second quarter.
Shares jump after the company receives some love from the analyst community.
CDMO earnings call for the period ending June 30, 2022.
CDMO earnings call for the period ending March 31, 2022.
CDMO earnings call for the period ending December 31, 2021.
CDMO earnings call for the period ending October 31, 2021.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.